

April 28, 2025

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sir/Madam,

Sub: Outcome of Board Meeting of the Company held on April 28, 2025

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Monday, April 28, 2025, *inter-alia* considered and unanimously:

1. Approved the Audited Financial Results of the Company for the quarter and year ended March 31, 2025. A copy of the same is enclosed along with the Report of the Auditors thereon and a declaration stating that the said report is with unmodified opinion.
2. Recommended of final dividend of Rs. 20 (Rupees Twenty only) per equity share (250% on the face value of Rs.8 each) and additionally a special dividend of Rs. 4 (Rupees Four only) per equity share (50% on the face value of Rs. 8 each) on account of significant exceptional profit on assignment of land for the financial year 2024-25, subject to the approval of shareholders at the ensuing Annual General Meeting.
3. Approved the Audited Financial Statements of the Company, for the year ended March 31, 2025.
4. Based on recommendation of the Nomination and Remuneration Committee, approved appointment of Ms. Vasundhara Patni (DIN: 05015021), as an Additional Director in the capacity of Non-Executive Non-Independent Director of the Company w.e.f. April 28, 2025, subject to approval of shareholders at the ensuing Annual General Meeting and who shall be liable to retire by rotation. – Refer Annexure A.
5. Taken on record cessation of Mr. Yugal Sikri (DIN: 07576560), as the Managing Director of the Company on completion of his term at the end of business hours on April 30, 2025 – Refer Annexure B.
6. Based on recommendation of the Nomination and Remuneration Committee, approved continuation of Mr. Yugal Sikri (DIN: 07576560) on the Board by his appointment as a Non-Executive Non-Independent Director of the Company w.e.f. May 1, 2025, subject to approval of shareholders at the ensuing Annual General Meeting and who shall be liable to retire by rotation. – Refer Annexure C.
7. Taken on record cessation of Mr. Ashok Nair (DIN: 07906710) by resignation as a Senior Management Personnel of the Company at the end of business hours on April 30, 2025 – Refer Annexure D.
8. Based on recommendation of the Nomination and Remuneration Committee, approved appointment of Mr. Ashok Nair (DIN: 07906710) as an Additional Director in the capacity of Managing Director of the Company for a period

of 3 (three) years from May 1, 2025 to April 30, 2028, subject to approval of shareholders at the ensuing Annual General Meeting and who shall not be liable to retire by rotation. – Refer Annexure E.

9. Reconstituted the following committees of the Board:

Sustainability and Corporate Social Responsibility Committee			Stakeholders' Relationship Committee		
1.	Ms. Radhika Gupta	Chairperson	1.	Ms. Radhika Gupta	Chairperson
2.	Ms. Z. Khorakiwala	Member	2.	Mr. Anil Matai	Member
3.	Mr. Sachin Nandgaonkar	Member	3.	Mr. Ashok Nair	Member
4.	Mr. Ashok Nair	Member			

10. Appointment of Secretarial Auditors:

Based on the recommendations of the Audit Committee, approved appointment of M/s. Parikh Parekh & Associates, Practicing Company Secretaries, as the Secretarial Auditors of the Company for a period of 5 (five) consecutive years commencing from FY 2025-26 to FY 2029-30, subject to approval of the members of the Company at the ensuing Annual General Meeting.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Part A of Schedule III and SEBI Master Circular dated November 11, 2024, as amended from time to time. - Refer Annexure F.

11. Approved revision/change in the following Policy/Code:

- Nomination and Remuneration Policy.
- Code of conduct for Board Members and Senior Management.

The aforesaid amended policy/code and above information shall be made available on the Company's website at <https://www.rpglifesciences.com/>.

The meeting commenced at 03:00 p.m. and concluded at 6.30 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

Rajesh Shirambekar
Head – Legal & Company Secretary

(Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), 2015)

Annexure – A

1) Appointment of Ms. Vasundhara Patni (DIN: 05015021) as an Additional Non-Executive Non - Independent Director:

1	Reason for Change viz. appointment, reappointment, resignation, removal, death or otherwise	Appointment as an Additional Director in the capacity of Non-Executive Non-Independent Director.
2	Date of Appointment/ reappointment/cessation (as applicable) /reappointment/ term of appointment	April 28, 2025
3	Brief Profile (in case of appointment)	<p>Mrs. Vasundhara Patni is a Mumbai based innovative entrepreneur and business leader with over 15 years of experience across consumer goods, early childhood education, and clean beauty. She is the Founder and CEO of Kiro Beauty, one of India's first clean, toxin-free, vegan makeup brands.</p> <p>Her entrepreneurial journey started with the launch of The Ice Stone Factory, India's first "fresh-made" cold slab ice cream dessert chain, where she also led brand development, retail expansion and customer experience strategy across multiple outlets in Mumbai. She ventured into the education sector, developing early childhood programs in collaboration with educators from Harvard, MIT, and other leading US universities. The programs were focused on cognitive, emotional and physical development strategies for young children.</p> <p>In August 2020, recognizing a need in the Indian beauty market for high-performance, toxin-free cosmetics, Vasundhara founded Kiro Beauty. The brand offers 100% vegan, cruelty-free, and paraben-free products, combining indulgence with intentionality. Kiro's product line includes over 120 SKUs, featuring skincare-infused makeup that caters to modern Indian women.</p> <p>she holds a Bachelor of Arts and Science from the University of Pennsylvania with a major in Communications.</p>

4	Disclosure of relationships between directors (in case of appointment of a director)	Ms. Vasundhara Patni is daughter of Mr. Harsh V. Goenka, Chairman of the company.
5	Affirmation	As per declaration submitted to the Company, Ms. Vasundhara Patni has confirmed that she is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

Annexure – B

2) Cessation of Mr. Yugal Sikri (DIN: 07576560) as a Managing Director of the Company:

1	Reason for Change viz. Appointment, re-appointment, resignation, removal, death or otherwise;	Completion of term as Managing Director of the Company.
2	Date of Appointment/reappointment /cessation (as applicable) /reappointment Term of appointment	April 30, 2025
3	Brief Profile (in case of appointment)	Not Applicable.
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.

Annexure – C

3) Appointment of Mr. Yugal Sikri (DIN: 07576560) as a Non-Executive Non-Independent Director:

1	Reason for Change viz. Appointment, re-appointment, resignation, removal, death or otherwise;	Appointment as Non-Executive Non-Independent Director.
2	Date of Appointment/reappointment /cessation (as applicable) /reappointment Term of appointment	May 1, 2025
3	Brief Profile (in case of appointment)	<p>Mr. Yugal Sikri holds Master of Pharmacy Degree from IIT, BHU, Master of Marketing Management from Jamnalal Bajaj Institute of Management Studies and Certificates in Management from Thunderbird and Harvard Business Schools.</p> <p>Mr. Sikri is a senior pharma industry professional backed by over 35 years of rich and diverse experiences in managing successfully large businesses, building mega-brands and bringing in business turnarounds.</p> <p>He has been Chairman, Pharmaceutical Management at NMIMS School of Business</p>

	<p>Management, where he is credited with transforming its pharmaceutical management program, forging a strong academia-industry partnership and launching thought leadership initiatives.</p> <p>He has also been invited to be a mentor at Atal Incubation Center, a Government of India-NMIMS initiative, encouraging entrepreneurship amongst young start-ups. He was on the Board of RPG Life Sciences for past 2 years as an Independent Director.</p> <p>His work experiences come from senior leadership assignments at GlaxoSmithKline, Warner Lambert/ Pfizer, Novartis, Ranbaxy and RPGLS that includes Region Head of India, Srilanka and Nepal and Global Head of Marketing (Commercial functions) at Ranbaxy.</p>
--	--

Annexure – D

4) Resignation of Mr. Ashok Nair (DIN: 07906710) as Senior Management Personnel of the Company:

1	Reason for Change viz. Appointment, re-appointment, resignation, removal, death or otherwise;	Resignation as a Senior Management personnel of the Company member.
2	Date of Appointment/reappointment/cessation (as applicable) /reappointment/ Term of appointment	April 30, 2025
3	Brief Profile (in case of appointment)	Not Applicable.
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.

Annexure – E

5) Appointment of Mr. Ashok Nair (DIN: 07906710) as Managing Director:

1	Reason for Change viz. Appointment, re-appointment, resignation, removal, death or otherwise;	Appointment as Managing Director of the Company.
2	Date of Appointment/ reappointment/cessation (as applicable) /reappointment/ Term of appointment	May 1, 2025, Appointed for a period of 3 years subject to approval of the shareholders.
3	Brief Profile (in case of appointment)	<p>Mr. Nair is an established healthcare leader with 39 years of experience and successful track record of building new businesses and turning around existing ones. He has worked with a broad spectrum of companies, from mature ones to healthtech startups. His last corporate role was as the Managing Director of Abbott Primary Care.</p> <p>Through his long career, he worked with leading pharmaceutical companies such as Abbott, Torrent Pharma, Sun Pharma and Cipla; in areas such as sales, marketing, commercial and product management. He was also involved in formulating policy under the aegis of various industry bodies. More recently, he was a Co-Founder of WatchYourHealth, a B2B healthtech startup since June 2023. He also advised PE firms on healthcare topics.</p>
4	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Ashok Nair is not related to any Director or Key Managerial Personnel of the Company.
5	Affirmation	As per declaration submitted to the Company, Mr. Ashok Nair has confirmed that he is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

Annexure – F

6) Appointment of M/s. Parikh Parekh & Associates as s Secretarial Auditor of the Company:

1	Reason for Change viz. Appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of M/s. Parikh Parekh & Associates, Peer Reviewed Firm of Company Secretary, (CP No.: 9511), as the Secretarial Auditor of the Company.
2	Date of Appointment/reappointment /cessation (as applicable) /reappointment/ Term of appointment	For 5 (five) consecutive years commencing from FY 2025-26 up to FY 2029-30.
3	Brief Profile (in case of appointment)	<p>M/s. Parikh & Associates is a well-known firm of Practising Company Secretaries founded in 1987 and based in Mumbai. The firm has been Peer Reviewed and Quality Reviewed by the Institute of Company Secretaries of India (ICSI), ensuring the highest standards in professional practices.</p> <p>M/s. Parikh & Associates has a team of 35 members including 10 partners and focussed on providing comprehensive professional services in corporate law, SEBI regulations, FEMA compliance, and allied fields, providing solutions to ensure regulatory adherence and operational efficiency.</p> <p>The firm provides its services to various prominent companies and their expertise has earned the trust of industry leaders across sectors like banking, manufacturing, pharmaceuticals, and public utilities.</p>
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.